Clinical Trial

BS01 in Patients With Retinitis Pigmentosa

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
A Phase 1/2, Safety and Efficacy Trial of BS01, a Recombinant Adeno-Associated Virus Vector Expressing ChronosFP (AAV2-CAG-ChronosFP) in Patients with Retinitis Pigmentosa
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2020-02-18; most recent amendment 2026-01-21.
Status change: Active, Not Recruiting → Recruiting 2026-01-21
Status change: Recruiting → Active, Not Recruiting 2025-08-21
Trial Details
NCT Number NCT04278131
Lead Sponsor Bionic Sight LLC
Conditions Retinitis Pigmentosa
Enrollment 20 participants
Start Date 2020-02-06
Primary Completion 2026-12-30 (estimated)
Study Completion 2029-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-01-23